A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment

BACKGROUND: Cetuximab, a monoclonal antibody targeting Epidermal Growth Factor Receptor (EGFR), is currently used in metastatic colorectal cancer (mCRC), but predictive factors for therapeutic response are lacking. Mutational status of KRAS and EGFR, and EGFR copy number are potential determinants o...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonçalves, Anthony, Esteyries, Séverine, Taylor-Smedra, Brynn, Lagarde, Arnaud, Ayadi, Mounay, Monges, Geneviève, Bertucci, François, Esterni, Benjamin, Delpero, Jean-Robert, Turrini, Olivier, Lelong, Bernard, Viens, Patrice, Borg, Jean-Paul, Birnbaum, Daniel, Olschwang, Sylviane, Viret, Frédéric
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2432064/
https://www.ncbi.nlm.nih.gov/pubmed/18544172
http://dx.doi.org/10.1186/1471-2407-8-169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2432064/
https://www.ncbi.nlm.nih.gov/pubmed/18544172
http://dx.doi.org/10.1186/1471-2407-8-169

Ejemplares similares